Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Bioavailability Study on Healthy Volunteers
Interventions
BIOLOGICAL

Certolizumab pegol

Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg

BIOLOGICAL

Certolizumab pegol

Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg

BIOLOGICAL

Certolizumab pegol

200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg

Trial Locations (2)

Unknown

Rennes

Rueil-Malmaison

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY